Dearborn Partners’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.15M | Buy |
4,511
+207
| +5% | +$210K | 0.22% | 75 |
|
|
2025
Q4 | $4.63M | Sell |
4,304
-382
| -8% | -$365K | 0.23% | 73 |
|
|
2025
Q3 | $3.58M | Sell |
4,686
-186
| -4% | -$138K | 0.17% | 77 |
|
|
2025
Q2 | $3.8M | Sell |
4,872
-250
| -5% | -$194K | 0.18% | 76 |
|
|
2025
Q1 | $4.23M | Buy |
5,122
+180
| +4% | +$150K | 0.2% | 77 |
|
|
2024
Q4 | $3.82M | Buy |
4,942
+239
| +5% | +$198K | 0.16% | 80 |
|
|
2024
Q3 | $4.17M | Buy |
4,703
+55
| +1% | +$49.4K | 0.17% | 76 |
|
|
2024
Q2 | $4.21M | Buy |
4,648
+37
| +0.8% | +$29.6K | 0.18% | 76 |
|
|
2024
Q1 | $3.59M | Sell |
4,611
-66
| -1% | -$47K | 0.15% | 77 |
|
|
2023
Q4 | $2.73M | Buy |
4,677
+131
| +3% | +$76.5K | 0.1% | 79 |
|
|
2023
Q3 | $2.44M | Sell |
4,546
-134
| -3% | -$69K | 0.1% | 79 |
|
|
2023
Q2 | $2.19M | Buy |
4,680
+45
| +1% | +$18.9K | 0.08% | 77 |
|
|
2023
Q1 | $1.59M | Buy |
4,635
+55
| +1% | +$18.5K | 0.06% | 87 |
|
|
2022
Q4 | $1.68M | Sell |
4,580
-128
| -3% | -$45.4K | 0.07% | 90 |
|
|
2022
Q3 | $1.52M | Buy |
4,708
+128
| +3% | +$40.6K | 0.07% | 92 |
|
|
2022
Q2 | $1.49M | Buy |
4,580
+100
| +2% | +$30K | 0.06% | 97 |
|
|
2022
Q1 | $1.28M | Sell |
4,480
-14
| -0.3% | -$3.6K | 0.05% | 108 |
|
|
2021
Q4 | $1.24M | Hold |
4,494
| – | – | 0.05% | 108 |
|
|
2021
Q3 | $1.04M | Buy |
4,494
+6
| +0.1% | +$1.48K | 0.04% | 112 |
|
|
2021
Q2 | $1.03M | Hold |
4,488
| – | – | 0.04% | 115 |
|
|
2021
Q1 | $838K | Buy |
4,488
+135
| +3% | +$26.4K | 0.04% | 117 |
|
|
2020
Q4 | $735K | Buy |
4,353
+525
| +14% | +$78.4K | 0.03% | 127 |
|
|
2020
Q3 | $567K | Sell |
3,828
-349
| -8% | -$54K | 0.03% | 129 |
|
|
2020
Q2 | $686K | Buy |
4,177
+24
| +0.6% | +$3.68K | 0.04% | 112 |
|
|
2020
Q1 | $576K | Buy |
4,153
+667
| +19% | +$91.6K | 0.04% | 118 |
|
|
2019
Q4 | $458K | Hold |
3,486
| – | – | 0.02% | 146 |
|
|
2019
Q3 | $390K | Sell |
3,486
-27
| -0.8% | -$3.01K | 0.02% | 146 |
|
|
2019
Q2 | $389K | Sell |
3,513
-269
| -7% | -$31.7K | 0.02% | 141 |
|
|
2019
Q1 | $491K | Hold |
3,782
| – | – | 0.03% | 118 |
|
|
2018
Q4 | $438K | Sell |
3,782
-6
| -0.2% | -$670 | 0.03% | 127 |
|
|
2018
Q3 | $406K | Buy |
3,788
+888
| +31% | +$88.8K | 0.03% | 131 |
|
|
2018
Q2 | $247K | Hold |
2,900
| – | – | 0.02% | 155 |
|
|
2018
Q1 | $224K | Sell |
2,900
-370
| -11% | -$29.8K | 0.02% | 162 |
|
|
2017
Q4 | $276K | Hold |
3,270
| – | – | 0.02% | 151 |
|
|
2017
Q3 | $280K | Hold |
3,270
| – | – | 0.02% | 145 |
|
|
2017
Q2 | $269K | Hold |
3,270
| – | – | 0.02% | 144 |
|
|
2017
Q1 | $275K | Buy |
+3,270
| New | +$262K | 0.02% | 143 |
|
Other funds holding LLY
VCM
VPM
Dearborn Partners's LLY Position: Q1 2026 in Review
Dearborn Partners increased its Eli Lilly (LLY) stake by 4.8% in Q1 2026, buying an estimated $210K and bringing the position to 4,511 shares worth $4.15M. The position accounts for 0.22% of the portfolio, ranked #75.
Dearborn Partners first reported a position in LLY in Q1 2017 and has held it in 37 quarters since. The position peaked at $4.63M in Q4 2025. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Dearborn Partners held 4,511 shares of Eli Lilly worth $4.15M as of Q1 2026.
- Dearborn Partners bought 207 Eli Lilly shares in Q1 2026, an estimated $210K.
- Eli Lilly made up 0.22% of Dearborn Partners's portfolio in Q1 2026, its #75 holding.
- Dearborn Partners first reported a position in Eli Lilly in Q1 2017 and has held it in 37 quarters since.
- Dearborn Partners's Eli Lilly position peaked at $4.63M in Q4 2025.
- 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Dearborn Partners's 13F filing for Q1 2026, filed 12 May 2026.